Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Sutro Biopharma Releases 2025 Financial Results and Key Pipeline Updates: Driving Forward with Dual-Payload ADC Innovation and Extended Cash Runway
Executive Summary
- Clinical Milestones Achieved: Advanced multiple ADC programs, including three cohorts dosed in the Phase 1 STRO-004 trial and first patient dosing for the Astellas-partnered dual-payload iADC program.
- Wholly Owned Pipeline Progress: Unveiled STRO-227 (targeting PTK7) as the first wholly owned dual-payload program, with IND submission accelerated to 2026.
- Strengthened Financial Position: Cash runway extended into at least Q2 2028, following a successful \$110M capital raise in Q1 2026 and year-end cash of \$141.4M (excluding raise proceeds).
- Significantly Reduced Operating Expenses: Total R&D and G&A expenses dropped to \$207.4M from \$300.5M in 2024, reflecting operational restructuring and cost controls.
- Upcoming Catalysts: Initial clinical data for STRO-004 expected mid-2026; multiple presentations at AACR 2026 and other industry conferences.
- Milestone Payments: Expectation of \$17.5M in milestones in 2026 from Astellas collaboration.
Detailed Business Highlights and Pipeline Updates
Wholly Owned Pipeline
-
STRO-004 (Tissue Factor ADC):
- Three cohorts dosed in a first-in-human Phase 1 trial. Initial clinical data—including safety, tolerability, pharmacokinetics, and potentially early signs of anti-tumor activity—expected mid-2026.
- Preclinical studies show favorable safety (HNSTD of 50 mg/kg in NHPs, supporting a clinical starting dose of 1 mg/kg).
- Positioned as a potential best-in-class TF ADC for solid tumors.
-
STRO-006 (Integrin β6 ADC):
- Highly selective Topo1 ADC (DAR8) targeting ITGB6; clinical development expected to begin in 2026 for multiple solid tumors.
-
STRO-227 (PTK7-Targeting Dual-Payload ADC):
- Combines MMAE (DAR2) and a Topo1 inhibitor (DAR8); IND submission targeted for 2026.
Partnered Programs and Collaborations
-
Astellas Partnership:
- First dual-payload immunostimulatory ADC (iADC) targeting TROP2 entered the clinic, triggering a \$10M milestone (expected receipt Q2 2026).
- Second program entered IND-enabling tox studies in Q4 2025, triggering \$7.5M additional milestone payment.
- These collaborations highlight validation and potential future non-dilutive funding streams.
Scientific and Industry Engagement
-
American Association for Cancer Research (AACR) 2026:
- Multiple presentations, including oral and poster sessions, across the ADC pipeline (STRO-004, STRO-006, STRO-227, dual-payload HER2-ADC, and platform innovations).
- Key Astellas presentation on TROP2-targeted iADC demonstrates potent efficacy and favorable safety in nonclinical models.
-
16th World ADC London Summit:
- Sutro participated in plenary and panel discussions focused on dual-payload innovation, ADC differentiation, and collaborative models.
Financial Results
-
Cash, Cash Equivalents, and Marketable Securities:
- \$141.4 million as of December 31, 2025, prior to the \$110 million capital raise in Q1 2026.
- Cash runway expected into at least Q2 2028, not accounting for additional future anticipated milestone payments.
-
Revenue:
- \$102.5 million for FY 2025 (up from \$62.0 million in FY 2024), mainly from Astellas and Ipsen collaborations.
-
Operating Expenses:
- Total R&D and G&A expenses: \$207.4 million (down from \$300.5 million in 2024).
- Non-cash stock-based compensation: \$14.0 million (down from \$24.7 million); depreciation/amortization: \$7.3 million.
- Restructuring and related costs: \$4.1–\$4.3 million, mostly paid in Q4 2025.
-
Net Loss:
- Net loss of \$191.1 million for FY 2025 (improved from \$227.5 million in 2024); net loss per share of \$22.49 (vs \$29.40 in 2024).
-
Balance Sheet:
- Total assets: \$173.8 million; total liabilities: \$306.3 million; stockholders’ deficit: \$(132.5) million.
- Deferred royalty obligation increased to \$219.5 million from \$180.8 million, reflecting ongoing royalty financing arrangements.
Strategic and Corporate Updates
-
Capital Raise:
- Underwritten offering of 7,868,383 shares at \$13.98/share, yielding gross proceeds of \$110 million.
- Expected to further extend cash runway and support pipeline execution.
-
Operational Restructuring:
- Continued focus on cost discipline, with restructuring costs largely realized in Q4 2025.
-
R&D Day Highlights:
- Virtual R&D day in November 2025 showcased platform advancements and pipeline priorities, including the selection of PTK7 for the lead dual-payload candidate (STRO-227).
Key Investor Takeaways and Price-Sensitive Considerations
- Multiple upcoming clinical data readouts and regulatory filings in 2026 are significant potential share price catalysts.
- Strong cash runway reduces near-term financing risk and supports ongoing R&D activities.
- Milestone payments from Astellas provide non-dilutive funding and validate the platform.
- Restructuring and cost management have significantly improved financial flexibility.
- Active participation at major scientific conferences enhances visibility and potential partnering opportunities.
- Risks remain around clinical trial outcomes, regulatory reviews, and competitive landscape.
About Sutro Biopharma
Sutro Biopharma is a clinical-stage biotech company advancing a next-generation ADC platform, with unique capabilities in dual-payload and novel-format ADCs. Its cell-free synthesis platform enables the development of differentiated ADCs with enhanced efficacy, safety, and the potential to overcome treatment resistance in oncology. Sutro’s pipeline targets significant unmet needs in large oncology markets.
Contact Information
Disclaimer
This article is intended for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Investors should consult official filings and perform their own due diligence before making investment decisions.
View SUTRO BIOPHARMA, INC. Historical chart here
